Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data PALISADE BIO, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.02
0.26
0.26
0.02
0.01
0
0.3
0
0
Research and development
13.2
8.1
3.96
4.06
2.02
2.43
6.55
6.89
16
10.2
General and administrative
7.5
5.47
4.56
4.59
6.2
9.31
8.76
6.2
5.8
7.86
Operating expenses
20.7
13.6
8.52
8.65
9.3
41.9
15.7
13.3
14.9
18.1
Operating income
-20.6
-13.3
-8.26
-8.63
-9.3
-41.9
-15.7
-13.1
-14.9
-18.1
Interest expense
1.14
0.16
0.01
0.01
0.24
2.4
0.01
0.02
0.01
0.01
Interest income
0.06
0.07
0.08
0.07
0.03
Other non-operating income
-0.44
-2.36
3.33
0.28
-1.03
15.2
1.46
0.77
0.42
1.28
Income tax
0
0
0
0
0
0
0
Net income
-21.1
-15.7
-4.92
-8.35
-10.3
-26.6
-14.3
-12.3
-14.4
-16.8
EBITDA
-20.3
-13
-8.07
-8.49
-9.29
-41.9
-15.7
-13.1
-14.9
-18.1
EPS, basic
-142,408.00
-67,545.00
-18,012.00
-9,078.00
-2,795.00
-2,145.00
-248.04
-27.01
-10.19
-0.30
EPS, diluted
-142,408.00
-67,545.00
-18,012.00
-9,078.00
-2,795.00
-2,547.00
-248.04
-27.01
-10.19
-0.30
Shares, basic (weighted)
0
0
0
0
0
0.01
0.06
0.46
1.42
55.7
Shares, diluted (weighted)
0
0
0
0
0
0.01
0.06
0.46
1.42
55.7
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
15.2
6.67
5.79
5.11
0.71
10.5
12.4
12.4
9.82
133
Short-term investments
5
5
Receivables
0.01
0.31
0.29
0.02
0.06
0
0
0
0
Other current assets
0.65
0.4
0.36
0.51
0.12
1.01
2.35
0.9
0.67
0.84
Total current assets
20.9
12.4
6.51
5.65
0.9
11.5
14.7
13.3
10.5
134
Property, plant and equipment
0.27
0.17
0.09
0.04
0.01
0
0.01
0.01
0
0
Lease right-of-use assets
0.2
0.28
0.11
0.3
0.2
0.08
0
Intangible assets
0.99
0.88
0.76
0.67
0.15
Other non-current assets
0.02
0.01
0.02
0.87
0.69
0.49
0.27
0.07
Total assets
22.6
13.9
7.68
6.58
3.02
12.5
15.8
14.1
10.9
134
Accounts payable
2.54
1.32
1.76
0.7
1.11
0.77
Accrued liabilities
2.74
0.46
0.57
0.83
1.24
2.19
Short-term debt
3.71
1.05
0.09
Total current liabilities
7.33
1.51
1.05
1.22
8.08
2.5
3.01
2.59
3.24
4.64
Long-term debt
0.09
0
Lease liabilities
0.15
0.11
0
0.21
0.09
0
Other non-current liabilities
0.15
Total liabilities
11.3
5.37
1.63
1.46
10.1
5.15
3.28
2.74
3.39
4.96
Total debt
3.71
1.14
0.09
Paid-in capital
204
217
220
227
51.4
102
122
133
143
281
Retained earnings
-193
-209
-214
-222
-68
94.6
109
122
136
Other comprehensive income
0
0
-0
-0.01
-0
Shareholders' equity
11.3
8.52
6.05
-8.33
-16.6
7.37
12.5
11.3
7.49
129
Total equity
11.3
8.52
6.05
-8.33
-16.6
7.37
12.5
11.3
7.49
129
Total liabilities and equity
22.6
13.9
7.68
6.58
3.02
12.5
15.8
14.1
10.9
134
Shares outstanding
0
0
0
0
0
0.02
0.2
0.62
2.77
159
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-21.1
-15.7
-4.92
-8.35
-10.3
-26.6
-14.3
-12.3
-14.4
-16.8
Depreciation and amortization
0.34
0.29
0.19
0.14
0
0
0
0
0
0
Stock-based compensation
3.45
1.77
0.63
0.88
2.01
1.89
1.03
0.62
0.65
3.96
Deferred income tax
-6.81
19.3
-2.74
0.46
0
0
Change in receivables
0.03
-0.3
0.02
0.27
-0.06
0.08
0
Change in payables
0.88
-1.52
-0.04
-0.02
1.01
-2.4
0.4
-0.49
0.82
0.62
Cash from operations
-15.6
-13.4
-7.69
-7.26
-4.77
-14.8
-13.4
-11.1
-12.2
-10.8
Capital expenditures
-0.1
-0.01
-0
-0.01
0
-0.01
-0
0
Acquisitions
0
-3.33
0
Purchases of investments
-5
-5
Cash from investing
2.36
-0.09
5
-0.01
-0.05
-0.01
-0
0
Debt repaid
-4.57
-3.77
Stock issued
1.18
5.21
14.4
9.42
8.44
128
Cash from financing
23.7
4.99
1.81
6.59
1.89
24.6
15.3
11.2
9.58
134
Exchange rate effect
-0
-0
-0.01
-0.01
Net change in cash
10.5
-8.52
-0.89
-0.67
-2.88
9.78
1.89
0.05
-2.61
124
Free cash flow
-15.7
-13.4
-7.69
-4.77
-14.8
-13.4
-11.1
-12.2
Interest paid
0.99
0.12
0.01
0.01
0.06
0.06
0.01
0.01
0.01
0.01
Income taxes paid
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.45 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-7,070.0%
Operating income / revenue.
EBITDA margin
-7,070.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-6,388.0%
Net income / revenue.
Operating cash flow margin
-3,638.0%
Cash from operations / revenue.
Return on equity (ROE)
-26.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-25.1%
Net income / average total assets.
R&D / revenue
3,913.0%
Research and development expense / revenue.
Stock-based pay / revenue
2,577.0%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
0.2%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
1,627.0%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
118.1%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
1,135.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
104.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
113.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
3,830.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
882.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
584.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
24.3x
Current assets / current liabilities.
Quick ratio
24.0x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
23.9x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.09
Cash from operations / diluted weighted shares.
Book value per share
$0.70
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
505x
Market cap / revenue.
P/B
2.08x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.08x
Market cap / tangible book value, when positive.
EV/Sales
255x
Enterprise value / revenue.
Earnings yield
-12.6%
Net income / market cap (the inverse of P/E).
What was PALISADE BIO, INC.'s revenue in fiscal 2025?
PALISADE BIO, INC. reported revenue of $0.0 for fiscal 2025.
Was PALISADE BIO, INC. profitable in fiscal 2025?
No. It reported a net loss of $16.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.